Chris Nicol
Chris is the Chief Technology Officer of Wave Computing and the lead architect of the DPU architecture incorporated into Wave’s Deep Learning Computer. In addition to his duties as CTO, Chris leads the systems team developing products, the runtime software environment and benchmarking applications using deep learning frameworks.
Prior to Wave, Chris was Chief Technology Officer, Embedded Systems at NICTA, an Australian ICT R&D organization he helped to establish, where he supported over 20 R&D projects across 5 labs in hardware and software development for intelligent, secure, robust and power efficient embedded systems. Prior to NICTA, he founded Bell Labs Research in Australia and Agere Systems in Australia and he worked for AT&T Bell Labs, New Jersey.
He received the PhD degree from the University of New South Wales and the MBA from the Australian Graduate School of Management. He is an inventor on 21 U.S. patents. He has served on the TPC of ISSCC twice, and is serving his second term on the TPC of IEEE International Symposium on Low Power Electronics and Design.
Andrew Feldman
Andrew Feldman is co-founder and CEO of Cerebras Systems. He is an entrepreneur dedicated to pushing boundaries in the compute space. Prior to Cerebras, he co-founded and was CEO of SeaMicro, a pioneer of energy-efficient, high-bandwidth microservers. SeaMicro was acquired by AMD in 2012 for $357M. Before SeaMicro, Andrew was the Vice President of Product Management, Marketing and BD at Force10 Networks which was later sold to Dell Computing for $800M. Prior to Force10 Networks, Andrew was the Vice President of Marketing and Corporate Development at RiverStone Networks from the company’s inception through IPO in 2001. Andrew holds a BA and an MBA from Stanford University.
Carol Christopher
Christopher Caires
David Crean
David H. Crean, Ph.D is a Managing Director at Objective Capital Partners where he leads the firm’s life science investment banking transactions. Dr. Crean has in excess of 20 years of life sciences R&D and corporate development transactional experience in the pharmaceutical industry where he was responsible for leading mergers, acquisitions, licensing and collaborations, and establishing corporate strategy. David’s transaction experience in the life sciences sector includes sell-side, buy-side, licensing and capital raising activities. He has supported company and client engagements in both U.S. domestic and foreign transactions including Japan, China and Europe.
Prior to joining Objective Capital Partners, Dr. Crean served over 20 years in specialty pharmaceuticals; namely at Allergan (NYSE:AGN) and Aqua Pharmaceuticals, a private equity-backed company, prior to being sold to Almirall, SA. (BME:ALM). Dr. Crean has led transaction execution in a wide range of specialty areas including aesthetic and therapeutic dermatology, OTC skin care, neurological disorders / CNS, pain, inflammation, ophthalmology, oncology and diagnostics/ detection. His corporate pharmaceutical experience spans research and development expertise in small molecules, biologics, prescription drugs, OTC products and medical devices.
Dr. Crean’s pharmaceutical and biotechnology leadership experience includes serving in key leadership roles in the development and/or growth of many commercial portfolios including: BOTOX, LUMIGAN, JUVEDERM, LATISSE, ACZONE, TAZORAC, MONODOX, FLUOROPLEX, XOLEGEL and VERDESO. Concurrent with Objective Capital, Dr. Crean serves as a strategic business advisor for several life science companies, is an active member on BIOCOM’s Capital Development Committee and BIO International 2017 Partnering Committee and a contributing member on the Membership & Program Committees for the Association for Corporate Growth (ACG) in San Diego.
Dr. Crean holds a Masters of Business Administration Degree with a finance concentration from Pepperdine University School of Management. Additionally, he holds a Doctorate of Philosophy Degree in Biophysics and a Masters of Science Degree in Oncology from the State University of New York at Buffalo. Dr. Crean also earned a Bachelor of Science Degree in Biology from Canisius College.
Dr. Crean holds FINRA Series 79 and Series 63 licenses and is a Registered Representative of BA Securities LLC, Member FINRA SIPC.
Hasti Nazem
Hasti is part of the founding team of Kindra, leading product development and education. Kindra is developing innovative estrogen-free solutions targeting the top pain points of the 34+ symptoms of menopause. With nearly 10 years of experience at the intersection of life sciences, health and wellness, and consumer brand building, Hasti integrates targeted product formulation development with cutting edge technical advancements. Her deep scientific communications experience helps to empower consumers to better understand their health, and bridge gaps often overlooked in women's health. Hasti's work has been featured in has been featured in The New York Times, Forbes.com, (O) Oprah Magazine, Harper's Bazaar, Women's Health Magazine, and in healthcare public affairs and pharmaceutical trade association publications.